Food and Drug Administration, HHS

Weight of animal		Number of tablets per	
	dose		
Pounds	Tablet no. 1	Tablet no. 2	
2 to 4	1/2		
5 to 7	1		
8 to 12	1 1/2		
13 to 18	2		
19 to 25	2 1/2		
26 to 30		1	
31 to 44		1 1/2	
45 to 60		2	
61 to 74		2 1/2	
75 to 90		3	
91 to 104		3 1/2	
105 to 120		4	
	Pounds 2 to 4	Pounds Tablet no. 1 2 to 4	

- (ii) Indications for use. For the removal of tapeworms (Dipylidium caninum, Taenia pisiformis, Echinococcus granulosus); hookworms (Ancylostoma caninum, Uncinaria stenocephala); ascarids (Toxocara canis, Toxascaris leonina); and whipworms (Trichuris vulpis) and for the removal and control of tapeworm Echinococcus multilocularis in dogs.
- (iii) Limitations. Do not use in pregnant animals. Do not use in dogs weighing less than 0.9 kilogram (2 pounds) or puppies less than 3 weeks of age. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[59 FR 33908, July 1, 1994, as amended at 61 FR 29651, June 12, 1996]

§ 520.1880 Prednisolone tablets.

- (a) Specifications. Each tablet contains 5 or 20 milligrams prednisolone.
- (b) *Sponsor*. See No. 061690 in §510.600(c)(2) of this chapter.
- (c) Special considerations. (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate parturition followed by dystocia, fetal death, retained placenta, and metritis.
- (2) Do not use in viral infections. Systemic therapy with prednisolone is contraindicated in animals with peptic ulcer, corneal ulcer, and Cushingoid syndrome. The presence of diabetes, osteoporosis, predisposition to thrombophlebitis, hypertension, congestive heart failure, renal insufficiency, and active tuberculosis necessitates carefully controlled use. Some

- of the above conditions occur only rarely in dogs but should be kept in mind.
- (3) Anti-inflammatory action of corticosteroids may mask signs of infection.
- (d) Conditions of use—(1) Amount. Dogs: 2.5 milligrams per 4.5 kilograms (10 pounds) body weight per day. Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced until maintenance level is achieved.
- (2) *Indications for use*. For use in dogs as an anti-inflammatory agent.
- (3) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[57 FR 4718, Feb. 7, 1992, as amended at 60 FR 57832, Nov. 22, 1995; 63 FR 148, Jan. 5, 1998]

§520.1900 Primidone tablets.

- (a) *Specifications*. Each tablet contains 50 or 250 milligrams of primidone.
- (b) Sponsor. See No. 000010 in §510.600(c) of this chapter for use of 250 milligram tablets; see No. 000856 in §510.600(c) of this chapter for use of 50 and 250 milligram tablets.
- (c) Conditions of use in dogs—(1) Amount. Twenty-five milligrams of primidone per pound of body weight (55 milligrams per kilogram of body weight) daily.1
- (2) Indications for use. For the control of convulsions associated with idiopathic epilepsy, epileptiform convulsions, viral encephalitis, distemper, and hardpad disease that occurs as a clinically recognizable lesion in certain entities in dogs.¹
- (3) Limitations. The tablets may be administered whole or crushed and mixed with the food. When convulsions are frequent, the dosage should be divided and administered at intervals. Reduction in dosage should be made gradually and never be abruptly discontinued. Do not use in feline species,

¹These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.

§ 520.1920

as primidone appears to have a specific neurotoxicity in cats. Federal law restricts this drug to use by or on the order of a licensed veterinarian.¹

[42 FR 61594, Dec. 6, 1977, as amended at 43 FR 55386, Nov 28, 1978; 46 FR 8467, Jan. 27, 1981; 46 FR 57477, Nov. 24, 1981; 53 FR 40727, Oct. 18, 1988; 56 FR 37473, Aug. 7, 1991; 62 FR 35076, June 30, 1997]

§ 520.1920 Prochlorperazine, isopropamide sustained release capsules.

- (a) Specifications. Prochlorperazine, isopropamide sustained release capsules contain either:
- (1) 3.33 milligrams of prochlorperazine (as the dimaleate) and 1.67 milligrams of isopropamide (as the iodide), or
- (2) 10 milligrams of prochlorperazine (as the dimaleate) and 5 milligrams of isopropamide (as the iodide).
- (b) Sponsor. See No. 000069 in \$510.600(c) of this chapter.
- (c) Conditions of use. (1) The drug is used for the treatment of dogs in which gastrointestinal disturbances are associated with emotional stress.
- (2)(i) Capsules described in paragraph (a)(1) of this section are administered orally to dogs weighing from 4 to 15 pounds at the rate of 1 capsule twice daily. These capsules are administered orally to dogs weighing from 16 to 30 pounds at the rate of 1 or 2 capsules twice daily. For dogs weighing less than 4 pounds, administer orally an appropriate fraction of the contents of one of these capsules.
- (ii) Capsules described in paragraph (a)(2) of this section are given to dogs weighing 30 pounds and over at the rate of 1 capsule twice daily.
- (3) For use only by or on the order of a licensed veterinarian.

[40 FR 13838, Mar. 27, 1975, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995]

§520.1921 Prochlorperazine, isopropamide, with neomycin sustained-release capsules.

- (a) Specifications. Each capsule contains either:
- (1) Capsule No. 1: 3.33 milligrams of prochlorperazine (as the dimaleate), 1.67 milligrams of isopropamide (as the

iodide), and 25 milligrams of neomycin base (as the sulfate); or

- (2) Capsule No. 3: 10 milligrams of prochlorperazine (as the dimaleate), 5 milligrams of isopropamide (as the iodide), and 75 milligrams of neomycin base (as the sulfate).
- (b) Sponsor. See No. 000069 in \$510.600(c) of this chapter.
- (c) Conditions of use—(1) Amount. Administer capsules orally twice daily to dogs as follows:

Animal weight (pounds)	Number of cap- sules per dose	
Animai weight (pounds)	Capsule No. 1	Capsule No. 3
10 to 20 20 to 30 Over 30 Over 60	1 2 3	1 2

- (2) *Indications for use*. For treatment of dogs in which infectious bacterial gastroenteritis is associated with emotional stress.
- (3) Limitations. Do not continue medication longer than 5 days. Overdosage or prolonged administration may produce nephrotoxicity as manifested by albuminuria, presence of granular casts and depressed urinary output. If it is desirable to administer a vasoconstrictor, norepinephrine is the drug of choice. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[49 FR 14103, Apr. 10, 1984, as amended at 56 FR 50653, Oct. 8, 1991; 60 FR 55659, Nov. 2, 1995]

§ 520.1962 Promazine hydrochloride.

- $\begin{array}{lll} \hbox{(a)(1)} & Chemical & name. & \hbox{10-[3-$}\\ \hbox{(Dimethylamino)propyl]phenothiazine} \\ \hbox{monohydrochloride}. \end{array}$
- (2) Specifications. Conforms to N.F. XII.
- (3) *Sponsor*. See No. 000856 in §510.600(c) of this chapter.
- (4) [Reserved]
- (5) Conditions of use. (i) The drug is used for quieting excitable, unruly, or intractable horses. It is administered at a dosage level of 0.45 to 0.9 milligrams of promazine hydrochloride per pound of body weight mixed with an amount of feed that will be readily consumed.
- (ii) Do not use in horses intended for food